US 12,030,924 B2
Exosomes for immuno-oncology and anti-inflammatory therapy
Nuruddeen D. Lewis, Andover, MA (US); Yu Zhou, Somerville, MA (US); Sriram Sathyanarayanan, Lexington, MA (US); John Kulman, Belmont, MA (US); Douglas E. Williams, Boston, MA (US); Leonid A. Gaydukov, Tewksbury, MA (US); Ke Xu, Belmont, MA (US); and Shelly Martin, Stoneham, MA (US)
Assigned to LONZA SALES AG, Basel (CH)
Filed by LONZA SALES AG, Basel (CH)
Filed on Jul. 6, 2020, as Appl. No. 16/921,351.
Application 16/921,351 is a continuation of application No. 16/236,246, filed on Dec. 28, 2018, granted, now 10,723,782.
Claims priority of provisional application 62/723,267, filed on Aug. 27, 2018.
Claims priority of provisional application 62/611,140, filed on Dec. 28, 2017.
Prior Publication US 2020/0407419 A1, Dec. 31, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/715 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 14/475 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); C07K 14/57 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01)
CPC C07K 14/7151 (2013.01) [C07K 14/4703 (2013.01); C07K 14/475 (2013.01); C07K 14/52 (2013.01); C07K 14/5418 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/57 (2013.01); C07K 14/70532 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/7155 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/6018 (2013.01); A61K 2039/627 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/31 (2013.01); C07K 2319/60 (2013.01)] 18 Claims
 
1. A composition comprising:
an extracellular vesicle comprising a fusion protein comprising a prostaglandin F2 receptor negative regulator (PTGFRN) or a fragment thereof sharing at least 90% sequence identity with either SEQ ID NO. 1 or SEQ ID NO. 2, fused to an immunomodulating component.